Key statistics
As of last trade, Fate Therapeutics Inc (F6T:DUS) traded at 2.06, 10.93% above the 52 week low of 1.86 set on Nov 18, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.92 |
---|---|
High | 2.06 |
Low | 1.92 |
Bid | 2.19 |
Offer | 2.22 |
Previous close | 1.96 |
Average volume | 611.22 |
---|---|
Shares outstanding | 113.88m |
Free float | 111.40m |
P/E (TTM) | -- |
Market cap | 235.73m USD |
EPS (TTM) | -1.65 USD |
Data delayed at least 15 minutes, as of Nov 22 2024 15:31 GMT.
More ▼
Announcements
- Fate Therapeutics Presents 6-Month Follow-up Data on First Patient Treated in Phase 1 Autoimmunity Study with Fludarabine-free Conditioning and FT819 Off-the-shelf, 1XX CAR T-cell Product Candidate at ACR Convergence
- Fate Therapeutics Highlights FT522 Off-the-shelf, ADR-armed CAR NK Cell Product Candidate at 2024 ACR Convergence
- Fate Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates
- Fate Therapeutics Highlights Cancer-selective, HER2-Targeting Profile of FT825 / ONO-8250 CAR T-cell Product Candidate for Treatment of Advanced Solid Tumors at 2024 SITC Annual Meeting
- Fate Therapeutics Presents Pan-tumor Targeting Preclinical Data for FT836 MICA/B-targeted CAR T-cell Product Candidate at 2024 SITC Annual Meeting
- Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
- Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
- Fate Therapeutics to Present at 2024 Cantor Global Healthcare Conference
- Fate Therapeutics Reports Second Quarter 2024 Financial Results and Business Updates
- Fate Therapeutics Appoints Neely Mozaffarian, MD, PhD, FACR, to its Board of Directors
More ▼